Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at AUD 270.1, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the AUD 270.1 support.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • The firm trades with high earnings multiples: 54.99 times its 2021 earnings per share.
  • The company is not the most generous with respect to shareholders' compensation.
Ratings chart
Sector Biopharmaceuticals
1st jan.Capitalisation (M$)Investor Rating
CSL LIMITED-5.62%95 982
SAMSUNG BIOLOGICS CO.,LTD.-2.66%49 217
BIOGEN INC.14.47%43 131
CHONGQING ZHIFEI BIOLOGICAL..-2.71%34 529
ALEXION PHARMACEUTICALS, IN..0.13%34 282
CELLTRION HEALTHCARE CO LTD--.--%21 767
UCB4.29%20 218
GRIFOLS, S.A.1.05%17 467
INNOVENT BIOLOGICS, INC.10.48%17 286
SHENZHEN KANGTAI BIOLOGICAL..-13.52%15 593
BIOMARIN PHARMACEUTICAL INC..-7.22%14 769
ZAI LAB LIMITED21.12%14 430
BLOE BIOT0.00%11 637
CANSINO BIOLOGICS INC.32.69%10 373
-
SHANGHAI JUNSHI BIOSCIENCES..11.62%10 008
TWIST BIOSCIENCE CORPORATIO..34.07%9 209
More Results
Financials (USD)
Sales 2021 10 127 M - -
Net income 2021 2 246 M - -
Net Debt 2021 4 747 M - -
P/E ratio 2021 54,2x
Yield 2021 0,82%
Capitalization 122 B 94 657 M -
EV / Sales 2021 12,5x
EV / Sales 2022 11,6x
Nbr of Employees 27 000
Free-Float 100,0%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes